Communiqués Evotec SE Deutsche Boerse AG

Actions

EVT

DE0005664809

Recherche biotechnologique et médicale

Marché Fermé - Deutsche Boerse AG Autres places de cotation 20:55:27 11/08/2026			Varia. 5j.	Varia. 1 janv.
3,702 ^EUR	+1,15 %		+6,99 %	-32,20 %

06/08	Evotec et Odyssey Therapeutics s'associent pour développer des traitements contre les maladies auto-immunes et inflammatoires	MT
06/08	Evotec et Odyssey Therapeutics s'associent dans la recherche de traitements contre les maladies auto-immunes et inflammatoires	MT

Communiqués

06/08	Evotec and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases	EQ
06/08	Evotec : and Odyssey Therapeutics Enter AI-Enabled R&D Collaboration in Autoimmune and Inflammatory Diseases	PU
13/07	Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook	EQ
13/07	Ad hoc: Evotec Announces Preliminary Second Quarter and First Half 2026 Results and Updates Full-Year 2026 Outlook	EQ
30/06	Just – Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics	EQ
16/06	Evotec SE: Dr. Cord Dohrmann, sell	EQ
12/06	Evotec : Presence and Voting Results AGM 2026 68.764 KB (EVT Abstimmung Liste EN)	PU
11/06	Evotec Reports Results of the Annual General Meeting 2026	EQ
02/06	Evotec Appoints Rui Wang as Head of Global In Silico and AI	EQ
26/05	Evotec : Letter of the Chair of Supervisory Board to the Shareholders of Evotec 116,952 KB	PU
22/05	Evotec SE: Dr. Cord Dohrmann, sell	EQ
12/05	Evotec SE Successfully Placed €116.1 Million Convertible Bonds	EQ
12/05	Evotec SE launches approximately EUR 125 million convertible bond offering	EQ
08/05	Evotec : Current Company Presentation 1.325 MB (2026 05 EVT Company Presentation)	PU
07/05	Evotec : Convening and Agenda of the Annual General Meeting, PDF (AGM Agenda EN)	PU
06/05	Evotec : Presentation Analyst Call Q1 2026 results, 6 May 2026 (20260506 Presentation Q1 Results FINAL)	PU
06/05	Evotec : Interim Statement Q1 2026, PDF (Interim Statement Q1 2026 English)	PU
06/05	Evotec Announces First Quarter 2026 Results: Building Transformation Momentum	EQ
05/05	Evotec : Modified remuneration system of the Management Board on agenda item 9, PDF (Evotec Remuneration System 2026 EN)	PU
05/05	Evotec : Articles of Association, PDF (2026 02 10 Evotec SE Articles of Association english)	PU
05/05	Evotec : Power of attorney to the proxies of the Company, PDF (Power of attorney to the proxies of the Company)	PU
05/05	Evotec : Revocation of proxy, PDF (Revocation of proxy)	PU
05/05	Evotec : Data Protection Information for Shareholders, PDF (Evotec Data protection)	PU
05/05	Evotec : Convening and Agenda of the Annual General Meeting, PDF (2026 05 04 AGM Agenda EN)	PU
05/05	Evotec : Information pursuant to § 125 para. 1 AktG in conjunction with. §125 para. 5 AktG, Article 4 para. 1 as well as Table 3 of the Annex to the Implementing Regulation (EU) 2018/1212, PDF (Evotec Informationen pursuant to %C2%A7 125 AktG as well as Table 3 of the Annex to the Implementing Regulation EU 20181212)	PU